PriceTargets.com logo

Verve Therapeutics - VERV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.75
  • Forecasted Upside: 348.61%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.74 As of 12/20/2024 06:31 PM ET
▲ +0.58 (11.24%)

This chart shows the closing price for VERV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Verve Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VERV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VERV

Analyst Price Target is $25.75
▲ +348.61% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Verve Therapeutics in the last 3 months. The average price target is $25.75, with a high forecast of $40.00 and a low forecast of $14.00. The average price target represents a 348.61% upside from the last price of $5.74.

This chart shows the closing price for VERV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Verve Therapeutics. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/6/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$29.00 ➝ $32.00
11/6/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$20.00 ➝ $17.00
11/6/2024HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $14.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/12/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$30.00 ➝ $29.00
8/9/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$25.00 ➝ $20.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
4/8/2024HC WainwrightInitiated CoverageBuy$15.00
4/3/2024Stifel NicolausLower TargetBuy ➝ Buy$56.00 ➝ $40.00
2/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$35.00
11/13/2023William BlairReiterated RatingOutperform
9/13/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$22.00
8/29/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$22.00
8/15/2023GuggenheimLower TargetBuy ➝ Buy$56.00 ➝ $55.00
8/11/2023Credit Suisse GroupReiterated RatingNeutral ➝ Neutral$31.00
8/8/2023Lifesci CapitalReiterated RatingOutperform
4/13/2023Canaccord Genuity GroupInitiated CoverageBuy$29.00
3/22/2023William BlairReiterated RatingOutperform
2/1/2023Cantor FitzgeraldInitiated CoverageNeutral$21.00
12/15/2022The Goldman Sachs GroupInitiated CoverageSell$13.00
11/15/2022Credit Suisse GroupLower Target$37.00
11/8/2022Royal Bank of CanadaLower TargetOutperform$42.00 ➝ $35.00
10/6/2022Credit Suisse GroupInitiated CoverageNeutral$48.00
8/24/2022Stifel NicolausUpgradeHold ➝ Buy$32.00 ➝ $56.00
7/25/2022GuggenheimLower Target$56.00
7/18/2022BMO Capital MarketsBoost Target$48.00 ➝ $62.00
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$48.00
3/14/2022Stifel NicolausLower Target$58.00 ➝ $34.00
2/17/2022Royal Bank of CanadaInitiated CoverageOutperform$42.00
12/22/2021Lifesci CapitalReiterated RatingOutperform
9/23/2021Stifel NicolausInitiated CoverageHold$58.00
9/2/2021William BlairReiterated RatingBuy
7/12/2021JPMorgan Chase & Co.Initiated CoverageNeutral$50.00
7/12/2021Jefferies Financial GroupInitiated CoverageBuy$72.00
7/12/2021GuggenheimInitiated CoverageBuy$84.00
7/12/2021William BlairInitiated CoverageOutperform$92.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 12 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 4 very positive mentions
  • 62 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
Mentions as of
9/21/2024
  • 6 very positive mentions
  • 58 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2024
  • 6 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 9 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 9 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Verve Therapeutics logo
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.74
Low: $5.12
High: $5.76

50 Day Range

MA: $5.78
Low: $4.50
High: $7.19

52 Week Range

Now: $5.74
Low: $4.30
High: $19.34

Volume

3,819,461 shs

Average Volume

1,373,602 shs

Market Capitalization

$485.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Verve Therapeutics?

The following sell-side analysts have issued reports on Verve Therapeutics in the last year: Canaccord Genuity Group Inc., HC Wainwright, Royal Bank of Canada, and Stifel Nicolaus.
View the latest analyst ratings for VERV.

What is the current price target for Verve Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Verve Therapeutics in the last year. Their average twelve-month price target is $25.75, suggesting a possible upside of 348.6%. Stifel Nicolaus has the highest price target set, predicting VERV will reach $40.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $14.00 for Verve Therapeutics in the next year.
View the latest price targets for VERV.

What is the current consensus analyst rating for Verve Therapeutics?

Verve Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VERV will outperform the market and that investors should add to their positions of Verve Therapeutics.
View the latest ratings for VERV.

What other companies compete with Verve Therapeutics?

Other companies that are similar to Verve Therapeutics include Galapagos, Xencor, Evotec, Arcutis Biotherapeutics and Nurix Therapeutics. Learn More about companies similar to Verve Therapeutics.

How do I contact Verve Therapeutics' investor relations team?

The company's listed phone number is 617-603-0070 and its investor relations email address is [email protected]. The official website for Verve Therapeutics is vervetx.com. Learn More about contacing Verve Therapeutics investor relations.